ArticleCVIR endovascular2025
Splenic artery embolization for refractory ascites after liver transplantation: a single-center experience.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRefractory ascites (RA) is a rare but poorly understood complication following liver transplantation (LT). It is often associated with portal hyperperfusion, potentially driven by splenic hyperafflux. In such cases, splenic artery embolization (SAE) has been proposed as a minimally invasive and cost-effective therapeutic option to reduce splanchnic inflow and alleviate symptoms. MATERIALS AND
methodsThis retrospective study analyzed patients who underwent LT between August 2010 and September 2023 at IRCCS Azienda Ospedaliera-Universitaria di Bologna and were subsequently diagnosed with refractory ascites. Embolization of the splenic artery was performed using coils or plugs of variable caliber. Laboratory assessments included bilirubin, albumin, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and international normalized ratio (INR). Additionally, Child-Pugh and MELD scores were recorded. The severity and evolution of ascites were monitored through serial ultrasonographic follow-ups.
resultsA total of 12 patients met the inclusion criteria. No severe complications related to the procedure were observed. Among them, 9 patients (75%) experienced complete resolution of ascites and normalization of liver function within 9 months post-procedure. Three patients (25%) died during follow-up due to transplant-related complications unrelated to SAE in the first month after the procedure.
conclusionSAE is an effective treatment option for patients with refractory ascites following LT. The procedure resulted in significant improvement in ascites control and liver function in most patients. Good patient selection is essential for a good procedure outcome. Further research with larger patient cohorts and longer follow-up is needed to validate these results. LEVEL OF EVIDENCE: Level 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.